Capecitabine

Generic Name
Capecitabine
Brand Names
Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
Drug Type
Small Molecule
Chemical Formula
C15H22FN3O6
CAS Number
154361-50-9
Unique Ingredient Identifier
6804DJ8Z9U
Background

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication

Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.

Associated Conditions
Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
Associated Therapies
Chemotherapy

Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2005-09-19
Last Posted Date
2012-09-13
Lead Sponsor
University of Washington
Target Recruit Count
40
Registration Number
NCT00194727
Locations
🇺🇸

University of Washington; Seattle Cancer Care Alliance, Seattle, Washington, United States

Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer

First Posted Date
2005-09-19
Last Posted Date
2021-11-24
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
59
Registration Number
NCT00193128
Locations
🇺🇸

Atlanta Cancer Care, Atlanta, Georgia, United States

🇺🇸

Northeast Georgia Medical Center, Gainesville, Georgia, United States

🇺🇸

Integrated Community Oncology Network, Jacksonville, Florida, United States

and more 4 locations

A Phase III Trial For Patients With Metastatic Breast Cancer

First Posted Date
2005-09-19
Last Posted Date
2009-12-24
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
475
Registration Number
NCT00191152
Locations
🇲🇽

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Michoacan, Mexico

🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Taipei, Taiwan

🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Tao-Yuan, Taiwan

and more 1 locations

Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

Phase 3
Conditions
First Posted Date
2005-09-16
Last Posted Date
2013-09-17
Lead Sponsor
Velindre NHS Trust
Target Recruit Count
2421
Registration Number
NCT00182715
Locations
🇮🇪

Mater Misericordiae University Hospital, Dublin, Ireland

🇬🇧

Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom

🇬🇧

University College of London Hospitals, London, England, United Kingdom

and more 78 locations

Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2005-09-15
Last Posted Date
2009-08-06
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Target Recruit Count
12
Registration Number
NCT00169000
Locations
🇺🇸

Norris Cotton Cancer Center, Lebanon, New Hampshire, United States

Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2005-09-15
Last Posted Date
2016-07-12
Lead Sponsor
University of Pittsburgh
Target Recruit Count
40
Registration Number
NCT00177307
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer

Not Applicable
Terminated
Conditions
First Posted Date
2005-09-15
Last Posted Date
2015-05-20
Lead Sponsor
University of Michigan Rogel Cancer Center
Registration Number
NCT00176735

A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2005-09-15
Last Posted Date
2016-02-08
Lead Sponsor
University of Pittsburgh
Target Recruit Count
40
Registration Number
NCT00177255
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath